WHWK

Whitehawk Therapeutics Inc

• TipRanks·6h ago

  Whitehawk Therapeutics presents analysis of MUC16 at SGO

• Benzinga·6h ago

  Whitehawk Therapeutics Presents Three Posters From Real-World Analysis Supporting Therapeutic Potential Of Targeting Mucin 16 With Next-Gen ADC For Treatment Of Ovarian And Endometrial Cancers At SGO 2026 Annual Meeting

• Reuters·7h ago

  Whitehawk says Phase 1 trial tests MUC16-targeted ADC HWK-016 in gynecologic cancers

• TipRanks·3d ago

  JonesTrading Sticks to Their Buy Rating for Whitehawk Therapeutics (WHWK)

• TipRanks·03/27 16:38

  Whitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should Know

• TipRanks·03/20 10:30

  Analysts Conflicted on These Healthcare Names: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Relmada Therapeutics (RLMD)

• Reuters·03/17 20:30

  Whitehawk Therapeutics to present three preclinical ADC abstracts at AACR Annual Meeting 2026

• TipRanks·03/13 12:08

  Oppenheimer Sticks to Their Buy Rating for Whitehawk Therapeutics (WHWK)

• Seeking Alpha·03/12 19:10

  Whitehawk Therapeutics GAAP EPS of -$0.34

• TipRanks·03/12 16:40

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)

• Benzinga·03/12 12:15

  Whitehawk Therapeutics Q4 EPS $(0.34) Misses $(0.13) Estimate

• Reuters·03/12 12:10

  Whitehawk Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs

• TipRanks·03/12 12:07

  Whitehawk Therapeutics reports Q4 EPS (34c) vs. (67c) last year

• Reuters·03/12 12:03

  Whitehawk Therapeutics FY2025 net loss fell 68% to USD 20.6 million

• Dow Jones·03/12 12:01

  *Whitehawk Therapeutics 4Q Rev $0.00 Vs. $7.2M >WHWK